



A Half-Truth is Not the Whole Truth The AHA Position on **Saturated Fat**

Dr. Fabian M. Dayrit

Professor, Ateneo de Manila University, Philippines

Chairman, Scientific Advisory Committee for Health, Asian and Pacific Coconut Community

This second in this series of papers will present the biases in the American Heart Association's 2017 Presidential Advisory with respect to saturated fat. Although important differences in the metabolic properties of specific SFA have been known since 1960s, the AHA still considers all SFAs as one group having the same properties. There is abundant research available that supports the designation of C6 to C12 fatty acids as medium-chain fatty acids (MCFA). This is particularly relevant to coconut oil, which is made up of about 65% MCFA. Ignoring the evidence, AHA simply labels coconut oil as SFA. The AHA promotes half-truths, not the whole truth.

On June 16, 2017, the American Heart Association issued its AHA Presidential Advisory which repeated its recommendation to "shift from saturated to unsaturated fats" (Sacks et al., 2017). While this advisory did not present any new data, it provided a re-analysis of old data which selectively rejected some studies which it claims did not satisfy "rigorous criteria for causality," while reinforcing those which were favorable to its conclusions.

The first paper in this series (published in June 2017 issue of Indian coconut Journal) showed that the scientific basis upon which the AHA made its recommendations is flawed and the Dietary Guidelines

for Americans, which has been recommending a low-saturated fat diet for 35 years, has made Americans obese even as heart disease – the supposed concern of the AHA – has remained the top health problem.

This second article is focused on "saturated fatty acids," the fat that AHA wants us to minimize. This article analyzes the 2017 AHA Presidential Advisory and provide counter evidence from the scientific literature, including clinical studies, to show that much of the confusion that we have today regarding the role of these fats in a healthy diet stems from the selective use of scientific information regarding saturated fat. The 2017 AHA Presidential Advisory provided only half the truth on saturated fat.

SFA, MCFA and LCFA

Saturated fatty acids (SFAs) generally refer to the following linear carboxylic acids: caproic (C₅H₁₁CO₂H, C₆), caprylic (C₇H₁₅CO₂H, C₈), capric (C₉H₁₉CO₂H, C₁₀), lauric (C₁₁H₂₃CO₂H, C₁₂), myristic (C₁₃H₂₇CO₂H, C₁₄), palmitic (C₁₅H₃₁CO₂H, C_{16:0}), and stearic (C₁₇H₃₅CO₂H; C_{18:0}). SFAs share the same structural features, but differ in their molecular size. Because of the apparent similarity in their chemical structures, SFAs are often assumed to possess the same biochemical and physiological properties. This is not true.

Coconut oil is an important chemical feedstock for the oleochemical industry. It is hydrolyzed and separated into its individual fatty acids. Lauric acid (C12), the main component of coconut oil, has the highest commercial value and is used in manufacture of various surfactants. There was a need to find applications for the other fatty acids. In the 1960s, a new synthetic group of fats was developed – “medium-chain triglyceride” (MCT) – which was made up mainly of C8 and C10. This commercial mixture was later called “MCT oil” and the main component fatty acids, C8 and C10, were called “medium-chain fatty acids” (MCFA). Initial feeding studies on rats showed that MCT oil was non-toxic and did not lead to weight gain compared with lard (Senior, 1968). Human clinical trials later showed that MCT oil was useful for patients with lipid disorders and for weight loss and it became commercially available in mid-1960s (Harkins & Sarett, 1968). Since then, MCT oil has been widely used in clinical practice as a special dietary oil and has been classified by the US FDA as GRAS (generally recognized as safe) (FDA, 2012). Because of its wide commercial availability and safety, medical researchers use MCT oil in their research. Consequently, most medical researchers consider MCFA to include C8 and C10 only; by exclusion, they use the term “long-chain” fatty acids (LCFA) to mean the longer SFAs, C12 and longer.

This historical account clearly shows that the classification of MCFA as C8 and C10 was based on the commercial availability of MCT oil and not on scientific considerations, and its wide use in clinical research reinforced this. However, based on biochemical and physiological properties, the classification of MCFA should include the fatty acids from C6 to C12.

Numerous researchers consider MCFAs to include the fatty acids from C6 to C12 based on their metabolic properties (Bach & Babayan, 1982; St. Onge & Jones, 2002; McCarty & DiNicolantonio, 2016; Schonfeld & Wojtczak, 2016; TMIC, 2017). MCFAs possess special properties that differentiate them from LCFAs. This section will highlight some of the special characteristics of MCFAs in general, and C12 in particular, will show why using only the single category of “saturated fatty acid” is a half-truth.

SFAs in various fats and oils

All biological organisms and cells utilize different fatty acids to produce lipids that are characteristic of the organism and cell type to fulfill its structural or

functional requirements. The fatty acid profiles of the various vegetable oils are characteristic of the plant source (Codex, 2015). Coconut oil has a characteristic fatty acid profile that differs from other vegetable oils in terms of its fatty acid profile: almost 50% is C12, about 65% is C6 to C12, and 92% is saturated. In contrast, the fatty acid profiles of all other vegetable oils start mainly with C16 and contain a significant proportion of unsaturated fatty acids. For example, soybean oil and corn oil both contain over 50% C18:2 (linoleic acid, an omega-6 fatty acid) and over 80% total unsaturated fat. Even animal fats, such as beef fat and lard, contain a substantial amount of unsaturated fat. For example, both beef fat and lard contain about 60% total unsaturated fatty acids even though these are



often referred to as “saturated fat”. Clearly, the fatty acid composition of coconut oil is very different from those of animal fats, including butter.

Another feature that sets the group of MCFAs (C6 to C12) apart is that they are not generally present in human abdominal fat and liver fat, and they are not constituents of serum lipids, whether as triglycerides or phospholipids. Analysis of fats in the liver using mass spectral imaging analysis did not detect any MCFA; the smallest fatty acid found was C14 (Debcic et al., 2009). This is consistent with the claims that MCFAs (C6 to C12) comprise a separate category from LCFA and that the use of “SFA” as a common label for this group is incomplete.

Another distinguishing characteristic of the group of MCFA (C6 to C12) is that they are rarely found attached to cholesterol as fatty acid ester derivatives. Plasma cholesterol is attached to long chain saturated and unsaturated fatty acid esters, in particular C16:0, C18:0, C18:1, C18:2, and C20:4 (AOCS, 2014). That

is, LCFA and PUFA are involved with the circulation of cholesterol around the blood stream and cholesterol deposited in arterial plaques, not MCFA.

“Saturated fat” and “animal fat” in the scientific literature

The vast majority of epidemiological studies, starting from Ancel Keys (1957) to the present, have failed to distinguish MCFA and LCFA and make their conclusions using the gross category of SFA. Unlike PUFAs, which are differentiated as omega-6 and omega-3, most epidemiologists, except those who study coconut oil in the diet, ignore the differences between MCFA and LCFA. In fact, most doctors and nutritionists commit the error of lumping animal fats



and coconut oil into one category. Is it any wonder then that the wrong dietary advice has been made for coconut oil and C12?

There are, however, a few papers that have specifically addressed C12. In 2003, Mensink and co-workers combined the results of 60 controlled trials into a single analysis (called a meta-analysis) and calculated the effects of the amount and type of fat on the ratio of total cholesterol to HDL (high-density lipoprotein), as well as to lipids. They reported that C12 increased HDL so that the net effect was to decrease the ratio of total cholesterol to HDL, a beneficial result. On the other hand, the LCFAs C14 and C16:0 had little effect on the ratio, while C18:0 reduced the ratio slightly. This is certainly a favorable result for C12.

Interestingly, the 2017 AHA Presidential Advisory also disposed of the beneficial properties of HDL without adequate proof, proclaiming that now CHD

would be all about LDL: "...changes in HDL-cholesterol caused by diet or drug treatments can no longer be directly linked to changes in CVD, and therefore, the LDL-cholesterol-raising effect should be considered on its own."

Since HDL is generally considered a standard lipid indicator, it is incumbent upon the AHA to provide definitive evidence to support its claim that HDL is now useless as a predictor of CHD.

Today, several types of LDL particles are known. LDL particles can be small and dense LDL (sdLDL) or large and buoyant (lbLDL). sdLDL is more susceptible to oxidation producing oxidized LDL (oxLDL). Thus sdLDL is more atherogenic and has been shown to be a strong predictor of CHD, while large buoyant LDL is not (Toft-Petersen et al., 2011; Hoogeveen et al., 2014).

In a 10-year study in Finland on 1,250 subjects, the various types of lipoproteins – LDL, HDL, and oxLDL – were measured. The study concluded that oxLDL, in proportion to LDL and HDL, was a strong risk factor of all-cause mortality independent of confounding factors (Linna et al., 2012). Furthermore, it has also been reported that the ratio of triglyceride to HDL is also a predictor for coronary disease (da Luz et al., 2008). If this is the case, HDL should remain an important lipid parameter, contrary to the AHA proclamation.

In the case of LDL, the absence of data on sdLDL and oxLDL in early studies involving LDL measurements makes their conclusions questionable. Correlations which have been made between LDL and CHD cannot therefore be considered reliable.

Conclusion

The warnings against saturated fat started with Ancel Keys. Keys never showed any appreciation for the physiologic differences between medium-chain fat and long-chain fat. The AHA has adopted this position to ignore the distinction between MCFA and LCFA despite numerous advances in their science. Detailed comparison of the fatty acid composition shows that coconut oil is very different from animal fat and studies that assume that they are similar are therefore in error. These may be one of the reasons why the Dietary Guidelines have not worked. ■

To this conclusion, we can apply the warning that Benjamin Franklin once made:

“Half a truth is often a great lie.”

References: ● [AOCS] American Oil Chemists' Society Lipid Library (2014). Sterols 1. Cholesterol and Cholesterol Esters. (<http://lipidlibrary.aocs.org/Primer/content.cfm?ItemNumber=39303>, downloaded June 9, 2017.) ● Akkaoui M, Cohen I, Esnous C, Lenoir V, Sournac M, Girard J (2009). Modulation of the hepatic malonyl-CoA–carnitine palmitoyltransferase 1A partnership creates a metabolic switch allowing oxidation of de novo fatty acids. *Biochem. J.* 420: 429–438 ● Bach AC, Babayan VK (1982). Medium-chain triglycerides: an update. *Am. J. Clin. Nutr.* 36:950-962. ● Bremer J (1983). Carnitine-Metabolism and Functions. *Physiol. Rev.* 63(4):1420-1466. ● [Codex] Codex Alimentarius 210-1999, amended 2015, FAO. ● da Luz PL, Favarato D, Faria-Neto Jr, Lemos P; Chagas ACP (2008). High ratio of triglycerides to HDL cholesterol ratio predicts extensive coronary disease. *Clinics.* 63:427-32. ● Dayrit FM (2015). The Properties of Lauric Acid and their Significance in Coconut Oil. *J Am. Oil Chem. Soc.* 92:1-15. ● Dayrit FM (2017). The Warning on Saturated Fat: From Defective Experiments to Defective Guidelines. <https://www.apccsec.org/apccsec/apccsec-home.html>. ● Delany JP, Windhauser MM, Champagne CM, Bray GA (2000). Differential oxidation of individual dietary fatty acids in humans. *Am. J. Clin. Nutr.* 72(4):905-911. ● Debois D, Bralet M-P, Le Naour F, Brunelle XA, Laprevote O (2009). In Situ Lipidomic Analysis of Nonalcoholic Fatty Liver by Cluster TOF-SIMS Imaging. *Anal. Chem.* 81:2823–2831. ● [FDA] Food and Drug Administration. 2012. GRAS Notice (GRN) No. 449. <http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/GRASListings/default.htm> ● Goransson G (1965). The Metabolism of Fatty Acids in the Rat. VIII. Lauric Acid and Myristic Acid. *Acta physiol. scand.* 64: 383-386. ● Gunstone, F (1996). Fatty Acid and Lipid Chemistry. Blackie: London. ● Hamilton JA (1998). Fatty acid transport: difficult or easy? *J. Lipid Res.* 39:467–481. ● Harkins RW, Saret HP (1968). Medium-Chain Triglycerides. *J. Am. Med. Assoc.*, 203(4):272-274. ● Hoogveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, Couper D, Virani SS, Kathiresan S, Boerwinkle E, Ballantyne CM (2014). Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease. *Arterioscler Thromb Vasc Biol.* 34:1069-1077 ● Keys A (1957). Epidemiologic aspects of coronary artery disease. *J. Chron. Dis.* 6(5): 552-559. ● Knox E, VanderJagt DJ, Shatima D, Huang YS, Chuang LT, Glew RH (2000). Nutritional status and intermediate chain-length fatty acids influence the conservation of essential fatty acids in the milk of northern Nigerian women. *Prostaglandins Leukot Essent. Fatty Acids* 63(4):195-202. ● Kotronen A, Seppänen-Laakso T, Westerbacka J, Kiviluoto T, Arola J, Ruskeepää A-L, Yki-Järvinen H, Orešič M (2010). Comparison of Lipid and Fatty Acid Composition of the Liver, Subcutaneous and Intra-abdominal Adipose Tissue, and Serum. *Obesity* 18:937–944. ● Krebs HA, Hems R (1970). Fatty Acid Metabolism in the Perfused Rat Liver. *Biochem. J.* 119: 525-533. ● Linna M, Ahotupa M, Lopponen MK, Irljala K, Vasankari T (2012). Circulating oxidised LDL lipids, when proportioned to HDL-c, emerged as a risk factor of all-cause mortality in a population-based survival study. *Age and Ageing* 0: 1–4. ● Liu YC (2008). Medium-chain triglyceride (MCT) ketogenic therapy. *Epilepsia* 49(Suppl. 8):33–36. ● Mansson HL (2008). Fatty acids in bovine milk fat. *Food & Nutrition Research* 2008. DOI: 10.3402/fnr.v52i0.1821. ● Mattson FH, Volpenhein RA (1969). Relative rates of hydrolysis by rat pancreatic lipase of esters of C2-C18 fatty acids with C1-C18 primary n-alcohols. *J. Lipid Res.* 10:271-276. ● McCarty MF, James J Di Nicolantonio JJ (2016). Lauric acid-rich medium-chain triglycerides can substitute for other oils in cooking applications and may have limited pathogenicity. *OpenHeart* 3:e000467. doi:10.1136/openhrt-2016-000467. ● Mensink RP, Zock PL, Kester ADM, Katan MB (2003). Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL-cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am. J. Clin. Nutr.* 77:1146–1155. ● Sacks FM, Lichtenstein AH, Wu JHY, Appel LJ, Creager MA, Kris-Etherton PM, Miller M, Rimm EB, Rudel LL, Robinson JG, Stone NJ, Van Horn LV (2017). Dietary Fats and Cardiovascular Disease, A Presidential Advisory From the American Heart Association. *Circulation.* 2017;135:e1-e24. ● Schon H, Gey F, Strecker FJ, Weitzel G (1955). Metabolic studies with fatty acids of intermediate chain length. III. Feeding experiments with lauric acid esters. *Hoppe Seylers Z Physiol Chem.* 301(3):143-155. ● Schonfeld P, Wojtczak L (2016). Short- and medium-chain fatty acids in the energy metabolism – the cellular perspective. *J. Lipid Res.* 57: 943-954. ● Senior JR (editor). 1968. Medium Chain Triglycerides, Univ. of Pennsylvania Press., cited in: Sulkers EJ, The use of medium-chain triglycerides in preterm infants. Thesis, Erasmus University Rotterdam, 1993. ISBN 90-9006053-7 ● Sigalet DL, Winkelaar GB, Smith LJ (1997). Determination of the route of medium-chain and long-chain fatty acid absorption by direct measurement in the rat. *JPEN J Parenter Enteral Nutr.* 21(5):275-278. ● [TMIC] The Metabolomics Innovation Center (2017). Metabocard for Dodecanoic acid. Canadian Institutes of Health Research, Alberta Innovates - Health Solutions, and The Metabolomics Innovation Centre (TMIC). <http://www.hmdb.ca/metabolites/HMDB00638> (downloaded: June 11, 2017). ● Toft-Petersen AP, Tilsted HH, Aarøe J, Rasmussen K, Christensen T, Griffin BA, Aardestrup IV, Andreasen A, Schmidt EB (2011). Small dense LDL particles - a predictor of coronary artery disease evaluated by invasive and CT-based techniques: a case-control study. *Lipids in Health and Disease* 2011, 10:21. <http://www.lipidworld.com/content/10/1/21>. ● You YQN, Ling PR, Qu JZ, Bistrrian BR (2008). Effects of Medium-Chain Triglycerides, Long-Chain Triglycerides, or 2-Monododecanoin on Fatty Acid Composition in the Portal Vein, Intestinal Lymph, and Systemic Circulation in Rats. *JPEN J Parenter Enteral Nutr.* 32(2): 169–175.